GlobeNewsWire
13 Jan 2026, 13:55 UTC · 37w ago
Verdict
Headline takes no side. We score MBRX +1.00 across three claims — strongly bullish.
+1.00strongly bullish
More positive than 99% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
An independent assessment confirmed no evidence of cardiotoxicity in 90 subjects treated with Annamycin across five clinical trials.
More positive than 99% of claims this week
65 of the 90 evaluated subjects received doses exceeding the FDA's lifetime maximum for other anthracyclines without showing cardiotoxicity.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 93% of claims this week
Moleculin has commenced the MIRACLE Phase 3 pivotal trial evaluating Annamycin in combination with cytarabine for relapsed or refractory acute myeloid leukemia (AML).
More positive than 87% of claims this week
Which stocks this story touches
More positive than 99% of ticker scores this week
The company received a positive independent assessment confirming the absence of cardiotoxicity for its lead drug candidate, Annamycin.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
6h ago
−86.0%
Price is moving against the score
$0.5677 vs $4.05 close before publication (Jan 12) · not market-adjusted
MBRX chart →
